Development and validation of a cuproptosis-immune prognostic signature for risk stratification and personalized therapy in cutaneous melanoma
Meiru Zhao, Meng Xiao, Xinmei Zhang, Junyan Zhang, Tong Liu, Huiping Wang · 2026
Read Development and validation of a cuproptosis-immune prognostic signature for risk stratification and personalized therapy in cutaneous melanoma by Meiru Zhao, Meng Xiao, Xinmei Zhang, Junyan Zhang, Tong Liu, Huiping Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13400501.txt.
Description
Zhao and co-authors construct, in 2026, a signature for cutaneous melanoma from genes linking cuproptosis, a copper-driven form of cell death, with immune activity. Starting from cancer atlas data, they identified 474 cuproptosis-related immune genes by correlation, then found 194 of them dysregulated in melanoma against normal tissue. Cox and LASSO methods distilled the list into a twelve-gene model used to split patients into high- and low-risk groups.
The training cohort held 406 patients, and an independent cohort of 208 patients validated the model. High-risk patients survived worse, with tumors showing reduced immune infiltration, suppressed checkpoint levels, and lower mutational burden, an immunosuppressed microenvironment profile. Low-risk tumors looked immune-inflamed, with higher mutational burden and checkpoint gene levels, suggesting better candidacy for checkpoint blockade. Drug response analysis hinted high-risk patients might benefit from other agents, making the signature a tool for therapy selection.
Catalog record
| CREATOR | Meiru Zhao, Meng Xiao, Xinmei Zhang, Junyan Zhang, Tong Liu, Huiping Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |